La Roche Posay Effaclar Medicated Cleanser

Description

No relevant information is available for SPL code 34089-3.

Uses and Indications

This drug is indicated for the treatment of acne.

There are no teratogenic effects associated with this medication. Additionally, no nonteratogenic effects have been reported.

Dosage and Administration

The product is to be used twice daily. Prior to application, the patient should wet their face thoroughly. A sufficient amount of the product should then be worked into a lather. The lather should be gently massaged onto the face, taking care to avoid contact with the eyes. After massaging, the product must be rinsed off well with water.

Contraindications

There are no specific contraindications listed for this product. However, it is imperative to seek immediate medical assistance or contact a Poison Control Center if the product is swallowed.

Warnings and Precautions

For external use only. It is imperative that this product is not ingested. In the event of accidental swallowing, immediate medical assistance should be sought, or the local Poison Control Center should be contacted without delay.

In cases where irritation occurs, it is advised to discontinue use and consult a healthcare professional. Furthermore, to minimize the risk of adverse effects, patients should refrain from using multiple topical acne medications concurrently. This precaution is essential to ensure safe and effective treatment outcomes.

Side Effects

For external use only. Patients should be advised to avoid contact with eyes and mucous membranes. In the event of accidental contact, thorough rinsing with water is recommended. No specific adverse reactions have been reported in clinical trials or postmarketing experiences beyond the stated warning.

Drug Interactions

Concurrent use of topical acne medications may increase the risk of skin irritation and dryness. It is advisable to limit the use of topical acne treatments to one at a time to minimize the potential for adverse effects. If irritation occurs, the patient should discontinue the use of additional topical acne medications and consult a healthcare professional for further guidance.

Packaging & NDC

Below are the non-prescription pack sizes of La Roche Posay Effaclar Medicated Cleanser (salicylic acid). Columns show Packaging, Formulation Type, and Active Ingredient Strength.

Pediatric Use

Pediatric patients should be advised to keep this medication out of reach of children. In the event of accidental ingestion, immediate medical assistance should be sought, or the Poison Control Center should be contacted without delay.

Geriatric Use

There is no specific information regarding the use of this medication in geriatric patients, including dosage adjustments, safety concerns, or special precautions. Healthcare providers should exercise caution when prescribing this medication to elderly patients, as individual responses may vary. Monitoring for potential adverse effects and therapeutic efficacy is recommended in this population.

Pregnancy

The product has not been specifically studied in pregnant patients, and therefore, there are no established safety concerns, dosage modifications, or special precautions regarding its use during pregnancy. Given the lack of data, healthcare professionals should weigh the potential benefits against any unknown risks when considering this product for women of childbearing potential. It is advisable to monitor pregnant patients closely if this product is deemed necessary.

Lactation

There is no specific information regarding the use of LA ROCHE POSAY EFFACLAR MEDICATED CLEANSER in lactating mothers or its effects on breastfed infants. Healthcare professionals should consider this lack of data when advising lactating mothers on the use of this product.

Renal Impairment

Patients with renal impairment have not been specifically addressed in the available prescribing information. There are no dosage adjustments, special monitoring requirements, or safety considerations outlined for individuals with reduced kidney function. Healthcare professionals should exercise caution and consider the lack of data when prescribing to this patient population.

Hepatic Impairment

Patients with hepatic impairment have not been specifically studied in clinical trials for this medication. Consequently, there is no available information regarding dosage adjustments, special monitoring requirements, or precautions for individuals with compromised liver function. It is recommended that healthcare providers exercise caution when prescribing this medication to patients with hepatic impairment, given the lack of data on its safety and efficacy in this population. Regular monitoring of liver function may be warranted based on clinical judgment.

Overdosage

In the absence of specific information regarding overdosage, healthcare professionals are advised to exercise caution and adhere to general principles of management in cases of suspected overdose.

It is essential to monitor the patient closely for any potential symptoms that may arise, as the clinical presentation can vary depending on the substance involved and the individual patient's response. Common symptoms of overdose may include, but are not limited to, altered mental status, cardiovascular instability, respiratory distress, and gastrointestinal disturbances.

In the event of an overdose, immediate medical attention should be sought. Healthcare providers should initiate supportive care, which may include maintaining airway patency, providing supplemental oxygen, and ensuring adequate circulation. The use of activated charcoal may be considered if the patient presents within a suitable timeframe and if the ingestion was recent.

Furthermore, specific antidotes or treatments may be indicated based on the substance involved in the overdose. It is crucial for healthcare professionals to consult relevant clinical guidelines and toxicology resources to determine the most appropriate management strategies.

In summary, while no specific overdosage information is available, vigilance and prompt intervention are paramount in managing potential overdose situations.

Nonclinical Toxicology

No teratogenic or non-teratogenic effects have been reported in the available nonclinical studies. Additionally, there is no information regarding animal pharmacology and toxicology. The absence of data limits the assessment of potential risks associated with the use of the compound in these contexts.

Postmarketing Experience

No postmarketing experience details are available in the insert.

Patient Counseling

Healthcare providers should advise patients to seek immediate medical assistance or contact a Poison Control Center if the medication is swallowed. It is crucial for patients to understand the potential risks associated with accidental ingestion.

Additionally, healthcare providers should inform patients about the likelihood of skin irritation and dryness when using this medication in conjunction with other topical acne treatments. Patients should be counseled to use only one topical acne medication at a time to minimize the risk of irritation. This guidance will help ensure safe and effective use of the medication while reducing the potential for adverse skin reactions.

Storage and Handling

The product is supplied in a configuration that ensures optimal usability. It should be stored at room temperature, away from excessive heat sources. To maintain product integrity, it is essential to keep the container tightly closed when not in use. Freezing the product is strictly prohibited, as it may compromise its effectiveness. If specified, the product should be discarded after opening to ensure safety and efficacy.

Additional Clinical Information

The medication is administered topically and should be applied twice daily. Clinicians should counsel patients that the use of another topical acne medication concurrently may increase the likelihood of skin irritation and dryness. In cases of irritation, it is advised to limit the use to one topical acne medication at a time. No further information is available regarding laboratory tests, abuse potential, or postmarketing experiences.

Drug Information (PDF)

This file contains official product information for La Roche Posay Effaclar Medicated Cleanser, including active ingredients, dosage, warnings, and labeling as submitted by the manufacturer for OTC distribution.

View product document (PDF)